Dosage, anticoagulant, and antithrombotic effects of heparin and low- molecular-weight heparin in the treatment of deep vein thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 1, 1997, Pages 83-90

  Harenberg, Job ^a   Stehle, Gerd ^a   Blauth, Matthias ^a   Huck, Kurt ^a   Mall, Kerstin ^a   Heene, Dieter L ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Deep vein thrombosis; heparin; laboratory monitoring; low molecular weight heparin; thrombus regression

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; THROMBIN;

ADULT; AGED; ANTICOAGULATION; BLOOD CLOTTING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; THROMBOSIS; THROMBUS;

EID: 0030958260     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996074     Document Type: Conference Paper

References (21)

1. Harenberg J, K Huck, H Bratsch, G Stehle, CE Dempfle, K Mall, M Blauth, KH Usadel, DL Heene: Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis 20(Suppl 1):205-219, 1990.
2. Salzman EW, D Deykin, RM Shapiro, R Rosenberg: Management of heparin therapy: Controlled prospective trial. N Engl J Med 292:1046-1050, 1975.
3. Hull R, G Raskob, J Hirsh, R Jay, J Leclerc, W Geerts, D Rosenbloom, D Sacket, CH Anderson, L Harrison, M Gent: Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 315:1109-1114, 1986.
4. Hommes DW, A Bura, L Mazzolai, HR Büller, JW ten Cate: Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med 116:279-284, 1992.
5. Wessler S, S Gitel: Control of heparin therapy. Prog Hemostas Thromb 3:311-329, 1976.
6. Basu D, A Gallus, J Hirsh, J Cade: A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 287:324-327, 1972.
7. Levine MN, A Planes, J Hirsh, M Goodyear, N Vochelle, M Gent: Relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparin to prevent deep vein thrombosis after hip replacement. Thromb Haemostas 62(Suppl 1):1640 (Abstr), 1989.
8. Leizorovicz A, G Simonneau, H Decousus, JP Boissel: Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis. Br Med J 309:299-304, 1994.
9. Lensing AW, MH Prins, BL Davidson, J Hirsh: Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 155:601-607, 1995.
10. Holm HA, B Ly, GF Handeland, U Abildgaard, KE Arnesen, P Gottschalk, V Hoeg, M Aandahl, K Haugen, F Laerum, B Scheel, O Sortland, B Vinje: Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin. Haemostasis 16(Suppl 1):30-37, 1986.
11. Bratt G, E Törnebohn, S Granqvist, W Aberg, D Lockner: A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep vein thrombosis. Thromb Haemostas 54:813-817, 1985.
12. Kirchmaier CM, E Lindhoff-Last, D Rubesam, I Scharrer, Z Vigh, G Mosch, H Wolf, HK Breddin: Regression of deep venous thrombosis by i.v. administration of a low molecular weight heparin - Results of a pilot study. Thromb Res 73:337-348, 1994.
13. Harenberg J, JX De Vries: Characterization of heparins by high performance size exclusion liquid chromatography. J Chromatogr 261:287-292, 1983.
14. White EM: Duplex sonography of the lower extremity venous system. In: Grant EG, EM White (Eds): Duplex Sonography. Springer, Berlin, 1988.
15. Rabinov K, S Paulin: Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 104:134-144, 1972.
16. Marder VJ, RL Soulen, V Atichartakran, AZ Budzynski, S Parulekar, KN Edward, J Zahavi, KM Algazy: Quantitative venographic assessment of deep venous thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 89:1018-1029, 1977.
17. Harenberg J: Modified anti-factor Xa chromogenic substrate assay for heparin and low molecular weight heparins. Ärztl Lab 33:39-41, 1987.
18. Harenberg J, C Giese, A Knödler, R Zimmermann: Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives. Haemostasis 19:13-20, 1989.
19. Denton J, DA Lane, L Thunberg, AM Slater, U Lindahl: Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 209:455-460, 1983.
20. Young E, P Wells, S Holloway, J Weitz, J Hirsh: Ex vivo and in vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemostas 71:300-304, 1994.
21. Barzu T, JLML van Rijn, M Petitou, P Molho, G Tobelem, JP Caen: Endothelial binding sites for heparin. Specificity and role in heparin neutralization. Biochem J 238:847-854, 1986.